Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Locally Advanced Bladder Cancer 1

Interventions

Rituximab 23Cyclophosphamide 11Radiotherapy 8Prednisone 8Vincristine 7Doxorubicin 7Lenalidomide 6Bendamustine Hydrochloride 5Chlorambucil 4Peripheral Blood Stem Cell Transplantation 3Filgrastim 3obinutuzumab 2liposomal amphotericin B 2idelalisib 2ibrutinib 2fludarabine phosphate 2VAP-cyclo protocol 2Therapeutics 2Psychiatric Rehabilitation 2Levofloxacin 2Interferon-alpha 2Idarubicin 2Epoetin Alfa 2Early Intervention, Educational 2Cyclosporine 2Busulfan 2zanubrutinib 1tafasitamab 1parsaclisib 1orelabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell, Marginal Zone × Pharmaceutical Preparations × Clear all
NCT00210353 2019-06-06

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 3 Completed
454 enrolled 16 charts
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡